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Abstract
Anemia is a common extraintestinal manifestation of inflam-
matory bowel disease (IBD), both in pediatric and in adult 
patients. Iron deficiency is the main cause of anemia in pa-
tients with IBD. Anemia is a clinically relevant comorbidity, 
with impact on patients’ quality of life and it should be time-
ly diagnosed and adequately treated. Currently, an active 
treatment approach is the recommended strategy, with evi-
dence showing efficacy and safety of intravenous iron for-
mulations. However, evidence in pediatric age remains 
scarce and no clinical recommendations exist for the diag-
nosis and treatment of this particular age group. The present 
document represents the first national consensus on the 
management of anemia in pediatric IBD and is therefore par-
ticularly relevant. The authors anticipate that the proposed 
recommendations will be useful in daily clinical practice for 
diagnosing and managing iron deficiency and iron-deficien-
cy anemia in the pediatric population with IBD.
© 2020 Sociedade Portuguesa de Gastrenterologia
Published by S. Karger AG, Basel
Consenso Português sobre o Diagnóstico, 
Tratamento e Abordagem da Anemia na Doença 
Inflamatória Intestinal Pediátrica
Palavras Chave
Anemia por défice de ferro · Anemia por doença crónica · 
Doença inflamatória intestinal · Infância · Idade Pediátrica
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
Portuguese Consensus on Anemia in 
Pediatric Inflammatory Bowel Disease
245GE Port J Gastroenterol 2020;27:244–254
DOI: 10.1159/000505071
Resumo
A anemia é uma manifestação extra-digestiva frequente 
associada à doença inflamatória intestinal, tanto na popu-
lação pediátrica como adulta, sendo a anemia por défice 
de ferro a sua forma mais frequente. Constitui uma co-
morbilidade clinicamente relevante, com repercussão na 
qualidade de vida. Deve ser atempadamente diagnosti-
cada e adequadamente tratada. A estratégia terapêutica 
atualmente aceite preconiza uma atitude interventiva. 
Neste contexto, a evidência científica atual tem demon-
strado a eficácia e segurança da utilização das formula-
ções de ferro endovenoso. Contudo, em idade pediátrica 
a evidência ainda é insuficiente, não existindo orienta-
ções de abordagem diagnóstica ou terapêutica especifi-
camente dirigidas a este grupo etário. Este é o primeiro 
consenso nacional sobre a abordagem da anemia na 
doença inflamatória intestinal pediátrica, revestindo-se 
por isso de particular relevância. Pretende-se que este 
documento tenha utilidade e aplicabilidade na prática 
clínica na avaliação e seguimento do défice de ferro e ane-
mia por défice de ferro em doentes pediátricos com doen-
ça inflamatória intestinal.
© 2020 Sociedade Portuguesa de Gastrenterologia
Publicado por S. Karger AG, Basel
Introduction
Anemia is the most common systemic complication 
and extraintestinal manifestation of inflammatory bowel 
disease (IBD), both in pediatric and adult populations [1–
5]. Anemia is a clinically relevant comorbidity, with im-
pact on patients’ quality of life and academic and profes-
sional capacity, and is associated with high health costs if 
left undiagnosed and untreated [6–8].
Although several etiologic factors may contribute to 
the development of anemia in patients with IBD, in most 
cases IBD-associated anemia is a unique example of the 
combination of chronic iron deficiency (ID) and anemia 
of chronic disease (ACD) [8–10]. This distinction is im-
portant for the choice of the most appropriate treatment.
The prevalence of anemia in adult IBD patients is vari-
able according to clinical setting – active versus remissive 
disease [3, 11, 12], inpatients versus outpatients [13] − 
and both ID and iron-deficiency anemia (IDA) have been 
reported in 16−76% of adult IBD patients [14]. In fact, the 
prevalence of anemia at annual follow-up in an adult pop-
ulation-based study in Sweden was 6% (5% for patients 
with ulcerative colitis [UC] and 9% for those with Crohn’s 
disease [CD], values rising to 35 and 50%, respectively, in 
hospitalization) [13]. In an observational cross-sectional 
multicenter study including 1,313 adult Portuguese IBD 
patients with a median follow-up after diagnosis of 7 
years, anemia was reported in 244 patients, representing 
a prevalence of 18.6% (95% CI 16.6−20.9) [15]. In an-
other multicenter study including a cohort of 1,871 adult 
patients, the prevalence of anemia was 49% in CD pa-
tients versus 39% in UC patients during the first 12 
months after diagnosis [16].
In pediatric IBD, the prevalence of anemia is not yet 
established, with available evidence suggesting a higher 
prevalence than reported in the adult population. A re-
cent retrospective cohort study in the US including 1,560 
CD and 886 UC children reported anemia in 51 and 43% 
of patients, respectively [17]. IDA is more frequent in CD, 
as shown in the study by Azzopardi and Ellul [18], in 
which 171 adult CD patients were investigated and ID 
was reported in 78% of those with active inflammation 
and 21% of those with quiescent disease.
The real prevalence of ID and IDA in the pediatric 
population with IBD remains unknown, with studies re-
porting higher rates than in the adult population. In 2012, 
an observational study reported a higher prevalence of ID 
in children (88%) and adolescents (83%) compared with 
adults (55%) [3]. In the same year, Wiskin et al. [5] re-
ported an ID prevalence of 70% in CD and 65% in UC 
pediatric patients 2 years after diagnosis. Recently, a ret-
rospective study of pediatric IBD patients reported a 
prevalence of IDA or a combination of IDA and ACD of 
28.85% at diagnosis and 15.38% at the 1-year follow-up 
[19]. Another study including pediatric hospitalized pa-
tients with IBD reported a 36% prevalence of IDA [20]. 
In a population-based retrospective Swedish study, ID 
was observed in 91% of children with IBD and remained 
highly prevalent despite clinical and biochemical remis-
sion (85% of ID cases, 34% of which with IDA) [21].
IBD-associated anemia should be timely diagnosed 
and adequately treated. Currently, an active treatment 
approach is the recommended strategy. In adult IBD pop-
ulations, although safety and efficacy of intravenous (IV) 
iron formulations have been demonstrated [22–29], it is 
not clearly established when to use IV iron or the tradi-
tional and recent oral iron therapies. Over the last decade, 
new IV iron formulations have emerged with a more fa-
vorable efficacy and safety profile, including iron sucrose 
and ferric carboxymaltose [30–32]. A recent review sug-
gested that oral iron should be preferred for patients with 
quiescent IBD disease and mild IDA, while IV iron sup-
plementation should be the best option for patients with 
active IBD and for those with inadequate response to or 
Lopes et al.GE Port J Gastroenterol 2020;27:244–254246
DOI: 10.1159/000505071
side effects with oral formulations [33]. In pediatric pa-
tients, evidence is still lacking, with no diagnostic or ther-
apeutic guidelines specifically focusing on this age group. 
Studies investigating IV iron formulations in pediatric 
patients are scarce [34, 35]. Recently published studies 
have shown encouraging data regarding safety and effi-
cacy of the new IV iron formulations − iron sucrose and 
ferric carboxymaltose − in the treatment of IDA in pedi-
atric patients with IBD [36, 37].
Due to the lack of robust data on the management of 
ID and IDA in pediatric IBD, it is critical to increase clin-
ical experience in the area, with clinical decisions sup-
ported by predefined recommendations and multicentric 
national-based studies.
The latest Portuguese [38] and European (ECCO) [39] 
consensus statements on the management of ID and ane-
mia in IBD do not specifically address the pediatric popu-
lation. However, ID is the most common nutritional def-
icit and IDA the most frequent form of anemia in this age 
group, and hence the opportunity to assess and monitor 
children’s iron reserves and to investigate ID and IDA 
diagnosis in this age group should always be assured. The 
importance of adequate iron reserves at this stage of life 
is acknowledged, as well as the impact of its deficit in chil-
dren’s cognitive performance, growth, immune regula-
tion, and quality of life [6, 8, 40].
The goal of this consensus, elaborated by the Portu-
guese Society of Pediatric Gastroenterology and Nutrition 
(SPGNP) – Anemia-IBD Working Group, is to propose 
recommendations for the management of anemia in pedi-
atric patients with IBD, based on ECCO [39] and on the 
Portuguese [38] consensus on anemia in IBD, specifically 
focusing on the features of ID and IDA in pediatric age.
Methodology
The strategy used for this consensus comprised several steps 
and followed the simplified Delphi procedure methodology [41]. 
A working group was predefined by selecting nine participants 
considered to be representative of national reference Pediatric 
Gastroenterology Centers and with clinical expertise in the area. 
Three working subgroups (WsG) were subsequently formed: 
WsG1 focusing on the diagnosis of anemia, WsG2 focusing on the 
treatment of non-anemia ID and IDA, and WsG3 focusing on 
monitoring and prevention of ID and IDA and other causes of 
anemia. Simultaneously, a comprehensive systematic literature re-
view of available evidence about anemia in pediatric and adult 
(whenever relevant) IBD populations between 2005 and 2018 was 
performed in PubMed and Medline.
For each WsG, relevant questions were raised based on current 
clinical practice and on evidence available in the literature, and a 
preliminary statement document was prepared based on partici-
pants’ answers to questions raised. The preliminary statement doc-
ument was reviewed by all participants, with inclusion of sugges-
tions, corrections, and inputs from all the experts. The final voting 
and consensus took place through face-to-face meeting.
Consensus for each statement was based upon an approval rate 
≥80% by the total working group (i.e., at least seven participants), 
with final possible answers for each statement being “agreement,” 
“disagreement,” or “neutral.” A ≥80% agreement was reached for 
every statement. Level of evidence (EL) was graded according to 
the Oxford Centre for Evidence-Based Medicine (www.cebm.net). 
Project coordinator Ana Isabel Lopes revised the final document.
Diagnosis of Anemia in IBD
Definition of Anemia
Although anemia in IBD is multifactorial, IDA is its 
most frequent form, followed by ACD (Table 1). Other 
causes contributing to anemia in IBD include vitamin B12 
and folic acid deficiency, as well as adverse effects of cer-
tain drugs, as salazopyrine, sulphasalazine, and azathio-
prine. ID is more common than IDA, as normal hemo-
globin (Hb) levels do not necessarily represent adequate 
iron stores.
Presence of anemia should be actively investigated and 
patients should be assessed for the presence of anemia 
throughout the different stages of disease. In pediatric 








Anemia of chronic disease
1. Alterations in distribution of iron stores
2. Immune-mediated alterations of iron transport pathways: 
reduced iron export from macrophages; functional iron 
deficiency; iron-deficient erythropoiesis
3. Inhibitory effect of inflammation on erythropoietin
Drug-induced anemia
1. Inhibition of differentiation and proliferation of erythroid 
precursors
2. Myelosuppression effect (indirect: “antifolic” effect of 
salazopyrine; direct: azathioprine)
3. Sulfasalazine: folate absorption impairment; hemolysis; 
aplasia
Vitamin B12 and folic acid deficiency
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age, expected growth spurts and disease-related growth 
spurts should be considered as a risk factor for ID and/or 
IDA development.
The World Health Organization (WHO) definition of 
anemia (Table 2) applies to pediatric IBD patients [42] 
and referred values should be considered for the diagno-
sis of anemia. Normal Hb levels vary according to age and 
gender, as well as with ethnicity, pregnancy status, alti-
tude, and smoking habits. Interpretation of Hb and he-
matocrit levels should take into consideration these mod-
ulating factors.
Children and adolescents with IBD have an increased 
risk of ID due to several causes. Some are not related 
with IBD, including increased growth requirements, 
nutritional imbalances due to dietary options, low so-
cioeconomic status, and migrant family context. In 
IBD, IDA may result from reduced ingestion and ab-
sorption, chronic gastrointestinal bleeding, and iron 
metabolism impairment (functional ID) related with 
proinflammatory state, as an increase in hepcidin re-
duces the action of ferroportin and hence iron absorp-
tion [43–48].
Statement 1
The diagnosis of anemia should consider Hb and he-
matocrit cut-offs defined by the WHO. All pediatric pa-
tients with IBD should be actively assessed for the pres-
ence of anemia, independently of disease activity. (Pe-
diatric EL 4; Adult EL 5)
Diagnosis Workup
The diagnosis of anemia should be based on labora-
tory assessment of the following parameters: complete 
blood count, serum ferritin, transferrin saturation, C-re-
active protein (CRP), and erythrocyte sedimentation rate 
(ESR). The frequency of screening will depend on disease 
activity and individual risk factors but should not be per-
formed more than 6 months apart and ideally planned 
according to periodic disease blood screening [3, 5, 49, 
50].
Statement 2
Investigation of anemia etiology should be initiated 
when Hb level is below the lower cut-off for age and 
gender. The minimum workup includes complete 
blood count, reticulocyte count, serum ferritin, trans-
ferrin saturation, ESR, and CRP. More extensive work-
up may include other parameters, as serum concentra-
tions of vitamin B12, folic acid, haptoglobin, lactate de-
hydrogenase, creatinine, and urea. Advice from a 
pediatric hematologist should be considered if the cause 
of anemia remains unclear after more extensive work-
up. (Pediatric EL 5)
Diagnosis of ID
When investigating the underlying cause of anemia, 
the most probable etiology should be considered. The 
workup includes red cell distribution width and mean 
corpuscular volume, mean corpuscular Hb, reticulocyte 
count, serum ferritin, transferrin saturation, CRP, and 
ESR. An integrated analysis of these parameters usually 
enables the diagnosis of IDA and/or ACD [8, 10].
The presence of normocytosis indicates ACD, micro-
cytosis indicates IDA (true or functional ID), and macro-
cytosis indicates vitamin B12 or folic acid deficiency. The 
mean corpuscular Hb is a marker of ID and is usually re-
duced in ID. However, concomitant vitamin B12 and folic 
acid deficiency and/or azathioprine may elevate this pa-
rameter, making it less reliable. Red cell distribution 
width is usually elevated in IDA and normal in ACD. 
However, certain factors − as hereditary anemias coexist-
ing in the same patient − may elevate this parameter, 
making it less useful when isolated.
In IBD, the distinction between IDA and ACD is im-
portant, since both conditions typically overlap, and 
treatment option relies on that distinction. By definition, 
IDA presents with reduced serum ferritin levels (this be-
ing the most important laboratory parameter in clinical 
practice), reduced serum iron, reduced transferrin satu-
ration, and elevated total iron fixation capacity. However, 
in the presence of inflammation, serum ferritin is usually 
elevated. In such cases (high ESR and CRP), serum fer-
ritin < 100 µg/L is considered an appropriate cut-off and 
is associated with iron depletion. In absence of inflamma-
tion, serum ferritin < 30 µg/L indicates ID. In both cases, 
transferrin saturation < 16% confirms the diagnosis of ID 
[8, 10]. New ID biomarkers are emerging and may be par-
Table 2. Minimum hemoglobin and hematocrit levels used to de-





6 months–5 years 11.0 33
6–11 years 11.5 34
12–13 years 12.0 36
Young nonpregnant female ≥14 years 12.0 36
Young pregnant female ≥14 years 11.0 33
Young male ≥14 years 13.0 39
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ticularly useful in cases of active inflammation, allowing 
a better distinction between IDA and ACD than the one 
achieved through serum ferritin and transferrin satura-
tion assessment.
Determination of the concentration of soluble trans-
ferrin receptor (sTfR) may also be particularly useful. 
sTfR is a transmembrane protein composed of two iden-
tical polypeptide chains stabilized by a disulfide bridge. It 
circulates in the plasma and its concentration is directly 
proportional to the total body mass of cellular transferrin 
receptor [47, 51–53]. sTfR is elevated in plasma in situa-
tions of increased bone marrow iron requirements, both 
in active erythropoietic activity and in ID (true or func-
tional). In the presence of inflammation (whether with 
normal or elevated ferritin), sTfR elevation is therefore a 
good indicator of iron-deficient erythropoiesis and IDA. 
In Portugal, this test is not yet available in most hospitals 
and hence its widespread use cannot be recommended in 
clinical practice.
Hepcidin and prohepcidin are iron metabolism regu-
lators, responsible for adjusting the amounts of serum 
iron according to body requirements. Their usefulness in 
IBD setting is not definitely established [43–45]. Other 
markers, as red blood cell size factor [43, 44], percentage 
of hypochromic red cells, and Hb concentration of re-
ticulocytes, may be useful markers to distinguish between 
IDA and ACD [39, 45].
When it is not possible to establish the underlying 
cause of anemia, additional tests may be necessary, in-
cluding serum concentrations of vitamin B12, folic acid, 
haptoglobin, lactate dehydrogenase, creatinine, and urea, 
as well as Hb electrophoresis and peripheral blood smear. 
If the cause of anemia remains unclear after more exten-
sive workup, advice from a pediatric hematologist is rec-
ommended [8, 10].
Statement 3
Diagnostic criteria for ID depend on the presence/
absence of inflammation. In patients with no evidence 
of active disease, serum ferritin < 30 μg/L is an appropri-
ate criterion. In patients with active disease, serum fer-
ritin < 100 µg/L is consistent with ID. (Adult EL 4)
Diagnosis of ACD
Inflammation has a profound effect on iron metabo-
lism and erythropoiesis. Hepcidin, a hepatic synthesis 
protein, plays a key role in ACD [44, 48]. Hepcidin syn-
thesis is reduced during erythropoiesis, assuring iron 
transport to the bone narrow. Hepcidin synthesis is driv-
en by inflammation, in a process mediated by interleukin 
(IL)-6 and involving the JAK/STAT3 pathway [45]. Oth-
er inflammatory cytokines, as tumor necrosis factor, may 
also directly reduce erythropoietin production and inhib-
it erythropoiesis. The increase in hepcidin, whether by 
chronic inflammation or by endoplasmic reticulum-asso-
ciated stress, favors iron depletion in the blood and its 
retention in the reticuloendothelial system − including in 
Kupffer cells −, thereby reducing iron transport to eryth-
roblasts, reducing transferrin saturation, and creating a 
state of functional ID for erythropoiesis [43, 44]. Addi-
tionally, hepcidin reduces iron absorption from the duo-
denum. Inflammatory cytokines also directly reduce 
erythropoietin production and inhibit erythropoiesis.
All these combined inflammatory mechanisms lead to 
a functional ID state, characterized by normal or elevated 
iron stores, reduced transport of iron from the macro-
phages, low plasma transferrin saturation, and restriction 
of iron availability in the bone marrow, overall contribut-
ing to reduce erythropoiesis. In IBD, the distinction be-
tween IDA and ACD is important, as both conditions fre-
quently overlap, and the choice of the appropriate treat-
ment is based on this distinction. Thus, in absence of 
biochemical or clinical evidence of inflammation, ID is 
likely if serum ferritin is < 30 μg/L. In presence of inflam-
mation, serum ferritin levels can be high despite empty 
iron stores. In such cases, 100 μg/L is considered an ap-
propriate cut-off level.
Statement 4
In the presence of biochemical or clinical evidence of 
inflammation, diagnosis of isolated ACD is based on 
serum ferritin > 100 μg/L and transferrin saturation  
< 20%. If serum ferritin level is between 30 and 100 μg/L, 
IDA and ACD likely coexist and IDA should be treated 
in these patients. (Adult EL 2)
Treatment of ID and IDA in IBD
In this section, only the therapeutic options for IDA, 
non-anemia ID, and ACD are addressed. Therapeutic op-
tions for vitamin B12/acid folic deficiency anemia, drug-
induced anemia, or other causes of anemia are not ad-
dressed.
Which Patients to Treat and How to Treat
Treatment of IDA should be offered to all IBD patients 
with Hb levels under the lower limit of normal for age and 
gender. In the presence of ID, iron supplementation 
should also be offered. The main goal of treatment is to 
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resolve anemia and achieve, at least, the lower limit of 
normal reference values for serum ferritin, serum iron, 
and transferrin saturation, assuring adequate iron stores. 
The lower the baseline Hb level, the longer the time re-
quired to normalize Hb. An increase in Hb ≥2 g/dL with-
in 4 weeks of treatment is an acceptable response [8, 39, 
49, 54].
Which Method of Iron Supplementation to Use
An increasing body of evidence suggests that IV iron 
formulations are safe and effective in the correction of 
IDA in pediatric non-IBD populations [26, 55]. In IBD, 
the clinical benefit of IV iron is well established in adults, 
with recent supporting data also emerging in the pediatric 
population.
Data supporting efficacy and safety of novel IV iron for-
mulations (ferric carboxymaltose and iron sucrose) in the 
treatment of ID and IDA in pediatric IBD has increased 
over the last years, with an increasing number of studies 
reporting correction of anemia and replenishment of ad-
equate iron stores at the end of treatment. Laass and col-
leagues [26] initially reported the efficacy of ferric carboxy-
maltose in pediatric patients with IDA and several gastro-
intestinal conditions by investigating a subgroup of 52 IBD 
patients (29 of which with CD) with a median age of 11.8 
years. Despite its retrospective nature and absence of long-
term follow-up, this study documented the efficacy of fer-
ric carboxymaltose in the correction of anemia (median 
Hb after treatment: 11.9 g/dL) and its favorable toxicity 
profile, with no report of adverse effects. In 2016, two stud-
ies confirmed these initial results [36, 55]. The study by 
Valério de Azevedo et al. [55] prospectively assessed the 
short-term efficacy and safety of IV iron during 40 months 
in 19 pediatric patients (median age 15.5 years) with CD 
and IDA with remissive/mild disease. The need for re-
treatment was also assessed by investigators. Results 
showed a median pre- and post-treatment Hb of 10.5  g/dL 
and 12.7 g/dL, respectively, with no major adverse effects. 
After a median of 15.5 months, 31.5% of patients required 
re-treatment. This study reinforced the importance of 
long-term follow-up of iron status in pediatric CD pa-
tients. The study by Danko and Weidkamp [36] prospec-
tively investigated 24 IBD children receiving 3 mg/kg (up 
to a maximum dose of 200 mg) of IV iron sucrose while 
receiving infliximab. The study showed an increase in 
mean ferritin, transferrin saturation, and Hb of 21.9 to 48.8 
ng/mL (p =  0.0004), 13.2 to 23.6% (p =  0.0009), and 11.4 
to 12.7 g/dL (p =  0.006), respectively. At the end of study, 
75, 63, and 79% of patients reached normal values for each 
parameter, respectively. No adverse reactions to treatment 
were reported. More recently, two studies confirmed the 
previously observed efficacy and safety data of new-gener-
ation IV iron formulations in pediatric patients with IBD 
[37, 56]. Stein et al. [37] retrospectively reviewed the charts 
of all pediatric patients with IBD receiving iron sucrose in-
fusions for IDA at a single center between 2011 and 2015. 
Seventy-two subjects were included (mostly [n = 53] with 
CD), 43 of which were included in the efficacy analysis. 
Investigators reported a significant mean Hb increase 
throughout the course of treatment, from 9.6 g/dL at base-
line to 12.1  g/dL after iron sucrose therapy (p <  0.001). 
Adverse effects were reported in 18.1% of subjects and 
6.6% of infusions, none of which life-threatening or requir-
ing hospitalization. The retrospective and single-center 
study by Papadopoulos et al. [56] analyzed the safety and 
efficacy outcomes of 41 children with IBD (mostly [56%] 
with UC) who received parenteral iron (ferric carboxy-
maltose, n = 35; iron sucrose, n = 7; both, n = 1) over 38 
months and showed a mean 2.5 g/dL, 8.4 g/dL, and 16.2% 
increase of Hb, iron levels, and transferrin saturation, re-
spectively. Three children developed mild rash after infu-
sion, which resolved quickly with chlorphenamine. Over-
all, the published evidence suggests encouraging safety and 
efficacy of novel IV iron formulations in the treatment of 
ID and IDA in pediatric patients with IBD.
The latest ECCO guidelines on the management of 
IDA in IBD recommend IV iron as first-line treatment, 
due to its safety, efficacy, good tolerability, and fast re-
sponse [22, 27, 39]. Although oral iron may be an option 
for mild anemia, it is less effective than IV iron, due to 
IBD-associated malabsorption [23–25, 28, 29], and re-
quires prolonged administration (minimum 3 months), 
being often associated with gastrointestinal intolerance 
[31–33].
Additionally, the effectiveness of treatment with oral 
iron may be impaired in patients with IBD due to disease 
activity – which reduces the intestinal iron absorption ca-
pacity – and unwanted gastrointestinal effects [34–36]. In 
patients with active disease, release of hepcidin in re-
sponse to IL-6 and IL-1b causes lower iron availability 
and reduced intestinal absorption of oral iron [44, 57, 58]. 
Unabsorbed iron is exposed to the ulcerated intestinal 
surface and may induce mucosal (oxidative) harm. In 
fact, studies in animal models of IBD have shown that lu-
minal iron may exacerbate disease activity [59–61]. If oral 
iron is considered a treatment option, the recommended 
dose is 3−6 mg/kg, up to a maximum of 100 mg/day.
New iron formulations, as ferric maltol, have shown 
few side effects in adult patients with IBD, even in those 
with a history of intolerance to ferrous sulfate [62, 63].
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Statement 5
IV iron should be considered as first-line treatment 
for all pediatric IBD patients with Hb > 6 g/dL (with he-
modynamic stability and no cardiovascular disease or 
other comorbidities). Oral iron may be a second-line 
option for patients with no gastrointestinal symptoms, 
in remission, with no previous history of oral iron in-
tolerance, and with mild anemia. (Pediatric EL 2b; 
Adult EL 1)
IV Iron Formulations Available in Portugal
Two IV iron formulations are approved by the Na-
tional Authority of Medicines and Health Products (IN-
FARMED) and available in Portugal for use in pediatric 
age: iron sucrose (< 14 years) and ferric carboxymaltose 
(≥14 years) [64]. Similarly to iron sucrose, ferric carboxy-
maltose does not require prior testing and allows the ad-
ministration of larger amounts of iron in a single dose.
Estimation of IV Iron Dosage Required
ECCO consensus states that the iron dose to adminis-
ter should be based on baseline Hb levels and body weight, 
and the Ganzoni formula (iron deficit [mg] = body weight 
[kg] × [target Hb – 385 actual Hb] [g/dL] 386 × 0.24 + 
500) [65] has been regularly used in the pediatric setting 
to calculate the IV iron dose to administer. The formula 
uses body weight to estimate iron store and iron needs, 
but some studies suggest that it may be error-prone and 
underestimate iron requirements. Studies also indicate 
that the simple ferric carboxymaltose dosing schemes 
(Tables 3 and 4) overestimate dosing requirements com-
pared with the Ganzoni formula [25, 64, 66–68].
The decision to treat ID in patients without anemia 
and the respective iron formulation to use is controversial 
in adult recommendations. Some authors propose IV 
iron formulations for patients with Hb < 12 g/dL and/or 
serum ferritin < 100 µg/L, due to the rapid recurrence of 
IDA in these patients [39, 66, 67]. The same authors rec-
ommend the administration of 500 mg of iron per dose 
and state that there is insufficient evidence to recommend 
iron for these patients, although with the new oral iron 
formulations, it may be considered an option (in remis-
sion patients).
Statement 6
The estimation of iron requirements should be based 
on baseline Hb and body weight (> 35 kg). (Adult EL 2) 
The traditional Ganzoni formula may be used for pa-
tients < 35 kg. (Adult EL 3b)
Monitoring for Treatment Response to IV Iron
Response to IV iron supplementation usually occurs 
within 4−6 weeks of treatment [49]. Hb levels allow to 
confirm correction of anemia. Effective iron store replen-
ishment may be estimated using a combination of serum 
ferritin, transferrin saturation, CRP, and/or ERS. The 
correlation with serum ferritin is not so good, as this ther-
apy induces the synthesis of ferritin and hence, its levels 
Table 3. Simplified scheme for estimation of the ferric carboxymaltose dose to administer
Hb, g/dL Body weight 35–70 kg Body weight ≥70 kg
10–12 (female) 1,000 mg 1,500 mg
10–13 (male) 1,000 mg 1,500 mg
7–10 1,500 mg 2,000 mg
Dose to administer <35 kg: 15 mg/kg until a maximum 20 mg/kg or alternatively use the Ganzoni formula 
(iron sucrose). Dose to administer for iron deficiency: 500 mg over 35 kg and 7.5–15 mg/kg for <35 kg (EL 5).
Table 4. Scheme for estimation of the ferric carboxymaltose dose to administer, considering patients with body 
weight under 35 kg
Hb, g/dL mmol/L Body weight <35 kg Body weight 35–70 kg Body weight >70 kg
<10 <6.2 500 mg 1,500 mg 2,000 mg
10–<14 6.2–<8.7 500 mg 1,000 mg 1,500 mg
≥14 ≥8.7 500 mg 500 mg 500 mg
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may be falsely elevated [26, 45, 63]. ECCO guidelines for 
the adult population with IBD state that post-treatment 
serum ferritin levels > 400 µg/L prevent recurrence of ID, 
suggesting that this value may be an indicator of adequate 
iron stores [39, 66]. Due to its only temporary elevation, 
transferrin saturation is also not a good medium-term 
indicator.
Statement 7
Evaluation of response to IV iron therapy and patient 
follow-up should be performed through complete 
blood count, CRP, and serum ferritin assessment. These 
laboratory assessments should be performed within 4 
weeks and until 12 weeks after treatment. (Adult EL 4)
Use of Transfusions of Red Cell Concentrates
The use of red cell concentrate transfusions should be 
reserved to clinically and hemodynamically unstable pa-
tients and/or with Hb < 6 g/dL and should be followed by 
IV iron treatment [8, 39]. Additionally, they should be 
considered for patients with Hb < 8 g/dL in need for a 
quick therapeutic response (e.g., surgery in the short 
term) [8, 39].
Monitoring and Prevention of ID and IDA Recurrence
When and How to Monitor Patients for ID and 
Anemia
ID and anemia monitoring in pediatric IBD patients 
should be included in the laboratory assessment plan ac-
cording to disease activity [3, 5, 39]. Iron status should be 
measured every 3 months during the first year after ane-
mia correction, and every 6 months thereafter [67, 69, 
70]. If an adequate Hb level is not reached after IV iron 
administration and/or inadequate iron stores persist, 
monitoring should be performed early and according to 
patient needs [67, 69]. In the presence of active disease, 
laboratory assessment of IDA and/or ID should be timely 
repeated, along with laboratory disease monitoring.
Statement 8
Pediatric patients with IBD should be monitored for 
recurrent ID at least every 3 months during the first 
year after correction, and every 6 months thereafter. 
(Pediatric EL 5)
Statement 9
The laboratory parameters for assessing recurrence of 
ID include complete blood count, serum ferritin, CRP, 
and ESR. (Pediatric EL 5)
When to Re-Treat ID and IDA
According to ECCO consensus, the goal of preventive 
treatment is to maintain Hb and serum ferritin levels 
within the normal range (EL 3) [39]. IDA frequently re-
curs after treatment. Evidence from the adult population 
shows that approximately 50% of patients have recur-
rence of ID or anemia within 10 months [66, 67]. The 
speed of recurrence relates with the size of iron stores af-
ter treatment, with post-treatment serum ferritin levels 
> 400 µg/L reported to prevent ID recurrence within the 
following 1–5 years [67].
The FERGImain study introduced the concept of a 
“proactive” approach to the management of anemia, in-
stead of the traditional “watch and wait” strategy [66]. 
According to this approach, preventive anemia treatment 
with IV iron should be initiated as soon as serum ferritin 
drops below 100 µg/L [39, 49]. According to the ECCO 
consensus, after successful treatment of IDA with IV iron, 
re-treatment with IV iron should be initiated as soon as 
serum ferritin drops below 100 µg/L or Hb drops below 
12 or 13 g/dL (according to gender) (EL 2) [39]. As the 
prevalence of anemia in children seems to be higher than 
in adults, both at diagnosis and during follow-up, these 
recommendations should also be applied when treating 
pediatric IBD patients. The use of oral iron for re-treat-
ment of pediatric patients with IBD may be considered 
for cases with mild ID or IDA, with clinically inactive dis-
ease, and with no previous intolerance to oral iron (see 
Statement 8). No studies are available to date on the effi-
cacy of oral iron in prevention of ID or IDA in pediatric 
IBD.
Statement 10
After correction of ID/IDA with IV iron, re-treat-
ment should be considered for patients with anemia re-
currence (serum ferritin < 100 µg/L or Hb under the 
lower limit of normal for age and gender). IV iron for-
mulations are the first-line treatment. Oral iron may 
also be an option. (Adult EL 2)
In pediatric age, the clinical approach largely relies in 
controlling the inflammatory activity of the disease and 
waiting for correction of anemia. However, studies have 
shown that the speed of anemia correction is too slow and 
a proactive approach should be adopted instead of a 
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watchful one [26]. Rapid anemia recurrence should raise 
clinical suspicion of inflammatory activity and adequate 
treatment should be promptly started. Coexisting IDA 
and ACD is frequent in these patients. Active treatment 
of IBD with the goal of maintaining disease remission 
leads to IDA/ACD resolution [8, 39, 49].
Statement 11
A rapid recurrence of anemia should raise clinical 
suspicion of IBD activity and prompt early assessment 
of disease activity and treatment initiation/escalation in 
parallel with anemia treatment. (Pediatric EL 5)
ECCO guidelines recommend the use of erythropoie-
sis-stimulating agents (erythropoietin, darbopoietin) in 
patients with IBD and anemia who have not responded 
satisfactorily to the therapy with IV iron [39]. This rec-
ommendation is supported by studies in rheumatologic 
patients with IDA receiving treatment with anti-tumor 
necrosis factor antibodies and also in patients with IBD. 
However, evidence in the pediatric population is still ab-
sent.
Statement 12
To date, there is no evidence on the use of erythropoi-
esis-stimulating agents in the treatment of IDA refrac-
tory to treatment with IV iron in the pediatric IBD pop-
ulation. (Pediatric EL 5)
Management of Non-ID Anemia
IDA usually presents with microcytosis (or normocy-
tosis if associated with ACD) and normal or reduced re-
ticulocytes. Consequently, assessment of these parame-
ters requires a different characterization, since the etiol-
ogy may not be obvious. The etiology of anemia in IBD is 
multifactorial, with the most frequent causes being IDA 
and ACD. Other causes are less frequent but should also 
be considered, including vitamin B12 and folic acid defi-
ciency, adverse effects of certain drugs (thiopurines, 
methotrexate), infections, or myelodysplastic syndromes. 
Patients submitted to small bowel resection or with severe 
small bowel disease require closer surveillance and should 
be annually monitored for serum levels of vitamin B12 and 
folic acid, or sooner if macrocytosis is present and sub-
jects are not receiving purine analogues. Mean corpuscu-
lar volume and reticulocyte count are important param-
eters for the management of non-IDA, as they allow dis-
tinguishing this condition from macrocytic anemia with 
low reticulocyte count (vitamin B12 and folic acid defi-
ciency, medications, myelodysplastic syndrome) [69].
Statement 13
The characterization of non-ID anemia should be 
performed based on mean corpuscular volume and re-
ticulocyte count. (Adult EL 5)
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